(f) if so, names of drugs and quantity involved alongwith amount paid on each during the last two years;

(g) what is the provision of DPCO under which each payment was made;

(h) whether there is any balance to be paid; and

(i) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The required details to the extent available will be collected and laid on the Table of the Rajya Sabha.

(c) No, Sir.

(d) The amounts will be recovered as per due process of law.

(e) Yes, Sir.

(f) An amount of Rs. 292.88 lakhs and Rs. 115·00 lakhs was/paid to M/s. IDPL from the DPEA during 1987-88 and 1988-89 respectively in respect of their claims prior to 1986-87. The claims related to bulk drugs of Analgin, Streptomycin Sulphate, Methl Dopa, 6A PA. Phenobarbit one etc.

(g) The payments were made under the provisions of DPCO, 1979 (now DPCO, 1987).

(h) and (i) An amount of Rs. 76 lakhs (approximately) is yet to be paid to M/s. IDPL in respect of their claims mentioned in the reply to part (f) of the question.

Price Control on Bulk Vitamins

139. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Vitamin B_1, B_2, B_6 and B_{12} are widely used and are also very important;

(b) whether it is a fact that Kelkar Committee also reiterated their recommendations for inclusion under price control in the supplementary report; and

(c) if so, what is the justification for delaying the action for bringing bulk vitamins under price control?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) Most of the drugs are widely used and are also important in various ways.

(b) and (c) Some of the recommendations contained in Supplementary report of the Kelkar Committee are yet to be examined.

Price Control on Glybenclamide

140. SHRI MOHD. KHALEELUR RAHMAN: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that his Ministry has price decontrolled Glybenclamide;

(b) whether it is also a fact that there is only one producer of this drug in the country;

(c) whether it is also a fact that they account for 95 per cent of the market of the formulations which is worth rupees five crores and enjoying the monopoly;

(d) whether it is also a fact that the company has increased the prices after decontrol;

(e) if so, what are the earlier and present prices;

(f) what were the basis taken by Kelkar Committee to recommend for price decontrol;

(g) whether it is a fact that Kelkar Committee recommended for inclusion of Polymixin, Methadilazine,